zurück

Cannabidiol (new indication: seizures associated with tuberous sclerosis complex (TSC); ≥ 2 years of age)

Subject:

  • Active Substance: Cannabidiol
  • Name: Epidyolex®
  • Therapeutic area: Seizures associated with tuberous sclerosis complex (TSC) 
  • Pharmaceutical company: GW Pharmaceuticals plc

Time table:

  • Start: 15.05.2021
  • Final decision by G-BA: 04.11.2021

Final decision:

  • Hint for a non-quantifiable additional benefit (orphan drug)